Patents by Inventor Joel D. Moore

Joel D. Moore has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Quinoxalinyl derivatives
    Patent number: 8962551
    Abstract: The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.
    Type: Grant
    Filed: December 3, 2008
    Date of Patent: February 24, 2015
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Deqiang Niu, Dong Liu, Joel D. Moore, Guoyou Xu, Ying Sun, Yonghua Gai, Datong Tang, Yat Sun Or, Zhe Wang
  • Quinoxalinyl macrocyclic hepatitis C virus serine protease inhibitors
    Patent number: 8809264
    Abstract: The present invention relates to compounds, including compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: June 26, 2007
    Date of Patent: August 19, 2014
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Deqiang Niu, Dong Liu, Joel D. Moore, Guoyou Xu, Ying Sun, Yonghua Gai, Datong Tang, Yat Sun Or, Zhe Wang
  • Macrocyclic hepatitis C virus serine protease inhibitors
    Patent number: 8501681
    Abstract: The present invention relates to compounds, including compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: June 26, 2007
    Date of Patent: August 6, 2013
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Deqiang Niu, Dong Liu, Joel D. Moore, Guoyou Xu, Ying Sun, Yonghua Gai, Datong Tang, Yat Sun Or, Zhe Wang
  • Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
    Patent number: 8383583
    Abstract: The present invention relates to compounds of Formula I, II, or III, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.
    Type: Grant
    Filed: October 24, 2008
    Date of Patent: February 26, 2013
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Joel D. Moore, Yat Sun Or, Zhe Wang
  • C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors
    Patent number: 8263549
    Abstract: The present invention relates to compounds of Formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.
    Type: Grant
    Filed: November 26, 2008
    Date of Patent: September 11, 2012
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Joel D. Moore, Yat Sun Or, Zhe Wang
  • Difluoromethyl-containing macrocyclic compounds as hepatitis C virus inhibitors
    Patent number: 8211891
    Abstract: The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: April 30, 2009
    Date of Patent: July 3, 2012
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Yonghua Gai, Dong Liu, Joel D. Moore, Yat Sun Or, Zhe Wang
  • Bicyclic, C5-substituted proline derivatives as inhibitors of the hepatitis C virus NS3 protease
    Patent number: 8030307
    Abstract: The present invention relates to compounds of Formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.
    Type: Grant
    Filed: November 26, 2008
    Date of Patent: October 4, 2011
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Joel D. Moore, Yat Sun Or, Zhe Wang
  • Hydrazide-containing hepatitis C serine protease inhibitors
    Patent number: 7906513
    Abstract: The present invention relates to novel hydrazide-containing compounds of Formula I or Formula II, including pharmaceutically acceptable salts, esters, or prodrugs thereof which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: April 26, 2007
    Date of Patent: March 15, 2011
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Joel D. Moore, Eric L. Elliott, Yat Sun Or, Zhe Wang
  • Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
    Patent number: 7718612
    Abstract: The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof, which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.
    Type: Grant
    Filed: August 2, 2007
    Date of Patent: May 18, 2010
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Joel D. Moore, Datong Tang, Yat Sun Or, Zhe Wang
  • DIFLUOROMETHYL-CONTAINING MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS
    Publication number: 20090274657
    Abstract: The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: April 30, 2009
    Publication date: November 5, 2009
    Inventors: Yonghua Gai, Dong Liu, Joel D. Moore, Yat Sun Or, Zhe Wang
  • Acylaminoheteroaryl hepatitis C virus protease inhibitors
    Patent number: 7605126
    Abstract: The present invention discloses compounds of formulae I and II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: August 11, 2006
    Date of Patent: October 20, 2009
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Deqiang Niu, Joel D. Moore, Dong Liu, Yonghua Gai, Zhigang Chen, Yat Sun Or, Zhe Wang
  • Phosphorus-containing hepatitis C serine protease inhibitors
    Patent number: 7582605
    Abstract: The present invention relates to phosphorus-derived compounds of Formula I or Formula II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof, which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: August 11, 2006
    Date of Patent: September 1, 2009
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Joel D. Moore, Deqiang Niu, Guoyou Xu, Dong Liu, Yat Sun Or, Zhe Wang
  • QUINOXALINYL DERIVATIVES
    Publication number: 20090180981
    Abstract: The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.
    Type: Application
    Filed: December 3, 2008
    Publication date: July 16, 2009
    Inventors: Deqiang Niu, Dong Liu, Joel D. Moore, Guoyou Xu, Ying Sun, Yonghua Gai, Datong Tang, Yat Sun Or, Zhe Wang
  • BICYCLIC, C5-SUBSTITUTED PROLINE DERIVATIVES AS INHIBITORS OF THE HEPATITIS C VIRUS NS3 PROTEASE
    Publication number: 20090180983
    Abstract: The present invention relates to compounds of Formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.
    Type: Application
    Filed: November 26, 2008
    Publication date: July 16, 2009
    Inventors: Joel D. Moore, Yat Sun Or, Zhe Wang
  • C5-SUBSTITUTED, PROLINE-DERIVED, MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS
    Publication number: 20090175822
    Abstract: The present invention relates to compounds of Formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.
    Type: Application
    Filed: November 26, 2008
    Publication date: July 9, 2009
    Inventors: JOEL D. MOORE, YAT SUN OR, ZHE WANG
  • MACROCYCLIC, PYRIDAZINONE-CONTAINING HEPATITIS C SERINE PROTEASE INHIBITORS
    Publication number: 20090123425
    Abstract: The present invention relates to compounds of Formula I, II, or III, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.
    Type: Application
    Filed: October 24, 2008
    Publication date: May 14, 2009
    Inventors: Joel D. Moore, Yat Sun Or, Zhe Wang
  • ACYCLIC, PYRIDAZINONE-DERIVED HEPATITIS C SERINE PROTEASE INHIBITORS
    Publication number: 20090035267
    Abstract: The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof, which can inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.
    Type: Application
    Filed: July 31, 2007
    Publication date: February 5, 2009
    Inventors: Joel D. Moore, Datong Tang, Yat Sun Or, Zhe Wang
  • Pyridazinonyl Macrocyclic Hepatitis C Serine Protease Inhibitors
    Publication number: 20090035272
    Abstract: The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof, which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.
    Type: Application
    Filed: August 2, 2007
    Publication date: February 5, 2009
    Inventors: Joel D. Moore, Datong Tang, Yat Sun Or, Zhe Wang
  • QUINOXALINYL MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS
    Publication number: 20090005387
    Abstract: The present invention relates to compounds, including compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: January 18, 2008
    Publication date: January 1, 2009
    Inventors: Deqiang Niu, Dong Liu, Joel D. Moore, Guoyou Xu, Ying Sun, Yonghua Gai, Datong Tang, Yat Sun Or, Zhe Wang
  • HYDRAZIDE-CONTAINING HEPATITIS C SERINE PROTEASE INHIBITORS
    Publication number: 20080269228
    Abstract: The present invention relates to novel hydrazide-containing compounds of Formula I or Formula II, including pharmaceutically acceptable salts, esters, or prodrugs thereof which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: April 26, 2007
    Publication date: October 30, 2008
    Inventors: JOEL D. MOORE, ERIC L. ELLIOTT, YAT SUN OR, ZHE WANG